It’s the second acquisition for BioMarin in 2025, as the company seeks to diversify its product portfolio after the ...

California biotech BioMarin Pharmaceutical Inc. will pay $4.8 billion in cash for Amicus Therapeutics, a Princeton rare disease company with a presence in Philadelphia, the two publicly traded ...

Philadelphia has lagged in biotech R&D jobs despite University of Pennsylvania scientists playing a leading role in ...

The U.K. government wants to boost the local life sciences industry, and it hopes to entice American venture capital firms to ...

The new saw: Development-stage biotechs are maturing. Their drugs are winning approvals and independent commercial launches ...

Venture capital firm Aditum Bio is going all-out for a new collaboration with Fosun Pharma, launching a subsidiary with the ...

After a year marked by dramatic ups and downs, William Blair analysts say 2026 could carry forward the industry’s current ...

Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.

First, the Direxion Daily S&P Biotech Bull 3X Shares (NYSE: LABU) seeks daily investment results, before fees and expenses, of 300% of the performance of the aforementioned biotech index. Second, the ...

The US Congress is poised to enact bipartisan legislation that would block some Chinese biotechnology companies from ...

Chai is building foundation models for drug discovery, specifically to predict interactions between molecules so they could be reprogramed for cures.

A combination of a relatively low-risk approval process, growing sales, and a very attractive valuation based on management's ...